Feasibility of Ambulatory Talc. Pleurodesis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDavid Rollins

About this trial

Patients with malignant pleural disease often experience a significant symptom burden and a short life expectancy. The cornerstone of their treatment is relieving breathlessness by draining fluid from around the lungs and attempting to prevent further fluid build up. Inpatient chest drainage and talc pleurodesis remains the most successful method of stopping the fluid build up but this often requires an average hospital stay of four days. This can be an inappropriate length of time for this patient group. Our study would investigate whether this treatment could be provided on an outpatient, ambulatory basis and facilitate a greater quality of life.

The investigators would assess deliverability of the trial protocol and collect patient feedback to see if our patients consider it an acceptable and worthwhile intervention.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Malignant pleural effusion

Life expectancy >30 days

WHO PS 1-2 (3 if due to dyspnoea)

Disqualifiers

Previous failed pleurodesis (on affected side)

Known non-expansile lung

Trial design

Design model

Single group

Treatments tested in this trial

  • ambulatory chest drain and talc pleurodesis

    Procedure/Surgery

    a chest drain will be inserted, fluid drained and medical talc instilled on an ambulatory basis

Treatment groups

15 Participants
are divided into 1 treatment group
Group A: outpatient drain and talc pleurodesisExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Success rate of delivery of the ambulatory pleruodesis protocol

Can the investigators successfully deliver the described ambulatory pleruodesis protocol within the 5 day time frame and what is the success rate of the protocol delivery.

Time frame
5 days

Secondary outcomes

1

Patient satisfaction / Patient related outcome measurement

Questionnaire on breathlessness and chest pain at day 5 and semi-structured interview on the patient experience of the intervention

Time frame
5 days
2

Patient satisfaction / Patient related outcome measurement

Questionnaire on breathlessness and chest pain at day 30 and semi-structured interview of the patient experience of the intervention

Time frame
30 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

David Rollins

Lead sponsor

North Tees and Hartlepool NHS Foundation Trust

Sponsor institution